The effect of donor alcohol abuse on outcomes following heart transplantation

Background Current guidelines recommend against the use of hearts from donors that abuse alcohol. We explored the effect of donor alcohol abuse (AA) on cardiac allograft function and outcomes in heart transplant (HTx) recipients. Methods Overall, 370 HTx recipients were divided into two groups: (a)...

Full description

Saved in:
Bibliographic Details
Published in:Clinical transplantation 2019-02, Vol.33 (2), p.e13461-n/a
Main Authors: Newman, Joshua, Liebo, Max, Lowes, Brian D., Ilias Basha, Haseeb, Peled, Yael, Cendrowski, Emily, Zolty, Ronald, Douglas, Dylan, Um, John Y., McGee, Edwin, Heroux, Alain, Raichlin, Eugenia
Format: Article
Language:English
Subjects:
Alcoholism - complications
atrial fibrillation
Cause of Death
diastolic dysfunction
donor characteristics
Female
Follow-Up Studies
Heart Diseases - epidemiology
Heart Diseases - mortality
heart transplantation
Heart Transplantation - mortality
Humans
Male
Middle Aged
Prognosis
Retrospective Studies
Risk Assessment - methods
Risk Factors
Survival Rate
Tissue Donors - supply & distribution
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Current guidelines recommend against the use of hearts from donors that abuse alcohol. We explored the effect of donor alcohol abuse (AA) on cardiac allograft function and outcomes in heart transplant (HTx) recipients. Methods Overall, 370 HTx recipients were divided into two groups: (a) the alcoholic donor group (AD, n = 58) and (b) the non‐alcoholic donor group (NAD, n = 312). Results Recipients in the AD group had a slower heart rate (86 ± 13 vs 93 ± 13, P = 0.004) and an increased incidence of early atrial fibrillation (AF) (30% vs 11%, P = 0.003). Echocardiographic left ventricular mass was higher among alcoholic donors (171.7 ± 66.7 vs 151.6 ± 54.7, P = 0.02). This difference remained present 1 year following HTx (185 ± 43 vs 166 ± 42, P = 0.007). E/E′ was higher in the AD group (9.5 ± 3.9 vs 8.4 ± 2.9, P = 0.04) and a larger number of AD recipients had a ventilatory equivalent for VCO2 > 34 (50% vs 31%, P = 0.04) on cardiopulmonary exercise test. There was no significant difference in rejection, cardiac allograft vasculopathy (CAV), or survival between the groups. Conclusions Our data suggest that donor AA does not impact rejection, CAV, or intermediate‐term survival, but may cause increased incidence of post‐HTx AF and impaired cardiac allograft diastolic function.
ISSN:0902-0063
1399-0012
DOI:10.1111/ctr.13461